Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Finlabo SIM Spa
|
$58.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Norda ASA Receives Notification of Claims Under Sellers Warranties from DiaSorin SpA's Biotrin International Limited, DiaSorin AB and DiaSorin Inc
Norda ASA announced that the buyer of the NorDiag business, DiaSorin SpA's Biotrin International Limited, DiaSorin AB and DiaSorin Inc has notified Norda ASA of a potential deficiencies claims totaling to approximately EUR 700,000 under the sellers warranty. Norda announced that and its legal advisors are evaluating the validity of the claim.
Latest Developments for Diasorin SpA
- DiaSorin SpA Confirms FY 2013 Revenues and EBITDA Guidance
- DiaSorin SpA Announces FDA Approval of Aldosterone Assay on CLIA; FDA Approval of TSH and fT4
- DiaSorin SpA Proposes to Distribute Dividend for FY 2012; Issues FY 2013 Revenues and EBITDA Guidance Below Analysts' Estimates
- DiaSorin SpA Proposes Distribution of Extraordinary Dividend; Confirms FY 2012 Revenues and EBITDA Margin Guidance
Latest Key Developments in Medical
- Share this
- Link this
- Digg this
Follow Reuters